Filing 2024 Q2 compared to 2024 Q1 by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
Rajeev Shah
Authorized Signatory
Boston, Massachusetts
14 Aug 2024
The shares of Eliem Therapeutics, Inc. listed in the Information Table with "OTR" investment discretion represent shares held by Sera Medicines, LLC ("Sera"). Funds advised by the Reporting Manager collectively own approximately 81% of the outstanding equity interests of Sera. Investment discretion with respect to the shares held by Sera is shared with individuals not affiliated with the Reporting Manager.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.